SEC Form 4Coverage since May 26, 2026
$NBIX insider trading
Over the last 12 months, Neurocrine Biosciences insiders reported no purchases and 16 sales totaling $21.7M across SEC Form 4 filings. 100% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $21.7M 16 events
- Events · 12m
- 16 Form 4 filings, grouped
- Insiders · 12m
- 7 distinct reporters
- 10b5-1 share
- 100% pre-arranged plans
Side
Price · $NBIX · 12Mvia TradingView
Top insiders · 12m
Cooke JulieChief Human Resources Officer5× · $5.8M
Delaet IngridChief Regulatory Officer3× · $3.7M
Norwalk Leslie V—2× · $438K
Onyia JudeChief Scientific Officer2× · $3.5M
Lippoldt DarinChief Legal Officer2× · $3.5M
All insider trades
16 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 28, 2026 | Norwalk Leslie VD | ▼ Sale | 1,250 | $182.01 | $228K | -44% | plan |
| Jul 10, 2026 | Delaet IngridChief Regulatory Officer · O | ▼ Sale | 4,367 | $181.02 | $791K | -21.2% | plan |
| Jul 9, 2026 | Lippoldt DarinChief Legal Officer · O | ▼ Sale | 10,000 | $179.6 | $1.8M | -15.4% | plan |
| Jul 9, 2026 | Delaet IngridChief Regulatory Officer · O | ▼ Sale | 14,571 | $178.65 | $2.6M | -47.3% | plan · 3 tranches |
| Jun 29, 2026 | Lippoldt DarinChief Legal Officer · O | ▼ Sale | 10,000 | $170.15 | $1.7M | -15.4% | plan · 3 tranches |
| Jun 5, 2026 | SHERWIN STEPHEN AD | ▼ Sale | 25,000 | $165.32 | $4.1M | -61.2% | plan · 5 tranches |
| Jun 4, 2026 | Norwalk Leslie VD | ▼ Sale | 1,250 | $168.06 | $210K | -30.6% | plan |
| Jun 2, 2026 | Cooke JulieChief Human Resources Officer · O | ▼ Sale | 3,520 | $158.59 | $558K | -13.6% | plan |
| Jun 2, 2026 | Cooke JulieChief Human Resources Officer · O | ▼ Sale | 9,521 | $157.62 | $1.5M | -26.9% | plan |
| Jun 2, 2026 | Cooke JulieChief Human Resources Officer · O | ▼ Sale | 4,216 | $156.77 | $661K | -10.6% | plan |
| Jun 2, 2026 | Cooke JulieChief Human Resources Officer · O | ▼ Sale | 5,466 | $155.46 | $850K | -12.1% | plan |
| Jun 2, 2026 | Cooke JulieChief Human Resources Officer · O | ▼ Sale | 14,214 | $154.83 | $2.2M | -24% | plan |
| Jun 1, 2026 | Onyia JudeChief Scientific Officer · O | ▼ Sale | 11,000 | $160.25 | $1.8M | -29.9% | plan |
| May 29, 2026 | Delaet IngridChief Regulatory Officer · O | ▼ Sale | 2,261 | $156.71 | $354K | -12.2% | plan |
| May 27, 2026 | Onyia JudeChief Scientific Officer · O | ▼ Sale | 11,000 | $155.53 | $1.7M | -29.9% | plan |
| May 26, 2026 | Boyer David W.Chief Corp. Affairs Officer · O | ▼ Sale | 3,888 | $156.64 | $609K | -33.3% | plan |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $NBIX feed.